

Unilateral syphilitic pseudo-retinitis pigmentosa - importance of clinical investigation: case report

Pseudoretinose pigmentar unilateral luética - importância da investigação clínica: relato de caso

Samilla Augusto Vieira de Araujo¹, Renata Zaltron Neumann¹, Francyne Veiga Reis Cyrino^{1,2,3}

1. Centro Avançado de Oftalmologia, Universidade de Ribeirão Preto, Ribeirão Preto, SP, Brazil.

2. Consultores de Retina e Vítreo, Ribeirão Preto, SP, Brazil.

3. Setor de Retina, Hospital de Clínicas, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil.

KEYWORDS:

Retinitis pigmentosa; Syphilis; Retinal degeneration; Retinal photoreceptor cells.

ABSTRACT

Retinitis pigmentosa (RP) is a hereditary dystrophy of the retina in which progressive destruction of the neurosensory retina occurs. Although unilateral RP was first described more than a century ago, it is not yet a well-defined entity. This is attributed to the difficulty of ruling out secondary causes, primarily infectious ones. In the present case, the patient presented a clinical picture similar to unilateral RP but with laboratory tests and clinical history that corroborated the hypothesis of pseudo-retinitis pigmentosa secondary to syphilis. Although there is no specific treatment for this case, its discussion becomes important because of the current exponential growth of syphilis.

PALAVRAS-CHAVES:

Retinose pigmentar; Sífilis; Degeneração retiniana; Células fotorreceptoras retinianas bastonetes.

RESUMO

A retinose pigmentar é uma distrofia hereditária da retina em que ocorre a destruição progressiva da retina neurosensorial. Os casos unilaterais, retinose pigmentar unilateral, apesar de ter sido descrito pela primeira vez há mais de um século ainda não é uma entidade bem definida. Isso ocorre pela dificuldade de descartar causas secundárias principalmente as infecciosas. No caso em questão, o paciente apresentou quadro semelhante a retinose pigmentar unilateral porém com exames laboratoriais e história clínica que corroboraram com a hipótese de Pseudoretinose Pigmentar secundária a Sífilis. Apesar de não se ter um tratamento específico para o caso a discussão se torna importante devido ao crescimento exponencial da Sífilis atualmente.

INTRODUCTION

Retinitis pigmentosa (RP) is an umbrella term used to characterize certain diseases in which progressive destruction of retinal photoreceptors occurs, particularly rods, responsible for light-dark adaptation. This is the earliest symptom of the disease and is called nyctalopia. RP is the most common hereditary dystrophy (1:5000) and is usually diagnosed while patients are still at a young age. Most cases are bilateral^{2,3} and associated with a mutation in the RPE65 gene.

As rod degeneration progresses, the clinical image worsens, with consequent loss of peripheral vision and visual field constriction, progressively evolving to macular impairment, which may cause visual impairment, macular edema, posterior subcapsular cataracts, glaucoma, and even blindness². Anatomically, its classic signs are a triad of retinal pigmentation shaped such as bone spicules, "waxy" pallor, and arteriolar attenuation^{2,3}.

Corresponding author: Samilla Augusto Vieira de Araujo. E-mail: samillaaraujo@yahoo.com.br.

Received on: September 26, 2020. **Accepted on:** December 15, 2020.

Funding: No specific financial support was available for this study. **Disclosure of potential conflicts of interest:** None of the authors have any potential conflict of interest to disclose.

How to cite: Araujo SA, Neumann RZ, Cyrino FV. Pseudoretinose pigmentar unilateral luética - importância da investigação clínica: relato de caso. eOftalmo. 2021;7(1):31-5.

DOI: 10.17545/eOftalmo/2021.0006

 This content is licensed under a Creative Commons Attribution 4.0 International License.

Diagnosis is based on the clinical history and the changes reported in fundus biomicroscopy. Complementary examinations, such as visual field measurement, show peripheral scotomas evolving to a tubular pattern. Electroretinography shows a reduction in photoreceptor function, particularly in rods. Fluorescein angiography is important for monitoring the condition, revealing the degree of destruction of the pigment epithelium.

Although unilateral retinitis pigmentosa (URP) was described more than a century ago, it is not yet a well-defined entity³. Certain cases have been reported, but it is difficult to exclude secondary diseases that present the same unilateral picture⁴. In 1952, François and Verriest established criteria for the correct diagnosis, according to which an association with infectious diseases or trauma should be excluded, and the presence of retinitis in the affected eye and the absence of signs in the contralateral eye must be attested⁵.

The aim of the present study is to report a case of infectious unilateral pseudo-retinitis pigmentosa (PRP) without an adequate diagnosis.

CASE REPORT

A male patient, 72-year-old, smoker, rural worker, attended a consultation at the Outpost for Advanced Ophthalmology of the University of Ribeirão Preto (CAO-UNAERP), Brazil, complaining of progressive loss of near vision in both eyes (OU) for ~2 years, more pronounced in the left eye (OS). He reported an electric welding accident injuring the OS > 20 years before, with no visual deficit at the time. He denied known comorbidities or family history of eye diseases and blindness.

A complete ophthalmological examination was performed with corrected visual acuity of 20/30 in the right eye (OD) and 20/25 in the OS, a nuclear cataract 2+ / 4+, and tonometry of 13 mmHg in OU. At funduscopy, the OD showed no changes (Figure 1); however, in the OS an optic disc with sharp margins could be observed, as well as a markedly pale papilla, vascular attenuation, and the presence of pigmentary lesions with the appearance of bony spicules diffused throughout the posterior pole and periphery, but sparing the macular region (Figure 2). These results suggested a probable diagnosis of URP.

Given these fundoscopic results, the patient was questioned again about his clinical history and reported risky sexual behavior as a young adult and

even after marriage. His wife reported that the patient had been treated with intramuscular penicillin a few years earlier.

Fluorescein angiography (FA), optical coherence tomography (OCT) (Figure 3), and a visual field test (Figure 4) were requested. The visual field test was normal in the OD, but a tubular field with a central vision island was evidenced in the OS. FA showed diffuse hypofluorescent areas of blockade mottled by window-effect hyperfluorescence in the four quadrants and in the macular region (Figure 3). OCT did not show any macular edema in the OS (Figure 4).

VDRL was non-reagent (1:1); other serology tests (FTA-ABS, toxoplasmosis, and cytomegalovirus) were all IgM-negative and IgG-positive.

DISCUSSION

Infectious diseases, such as syphilis, toxoplasmosis, rubella, and cytomegalovirus infection, can cause an inflammatory reaction leading to a mobilization of the retinal pigment epithelium (RPE)^{1,6} and the formation of bone spicule-shaped pigmented areas that are characteristic of RP. Other possible causes, such as eye trauma associated with retinal detachment⁷ or toxic retinitis secondary to the use of medications (such as antipsychotics) are significant and must be considered in the differential diagnosis⁸.




Figure 1. Retinography of the right eye showing absence of pathological changes in the periphery of the retina.

In the present study, despite the recent (two years) complaint of worsening visual acuity and the marked presence of fundoscopic changes only in the OS, the patient's history of risky sexual behavior and his good visual acuity suggested the hypothesis of PRP secondary to an infectious disease (syphilis). According to the literature, secondary conditions such as syphilitic PRP generally present more favorable visual prognosis than cases of hereditary RP, despite the risk of optic neuritis, which can lead to total loss of vision if not treated in time.

Until recently, there was no specific treatment for these disorders of the retinal epithelium. Certain

studies reported on the use of oral vitamin A for RP, but its effect was not proven beyond side effects⁹. The use of valproic acid was proposed in an attempt to slow the progression of the visual field, but no benefit was reported when compared to placebo⁸. Recently, voretigene neparvovec-rzyl (Luxturna[®]) was approved in the United States for treating RP. The candidates for this new treatment would be those patients who have a proven biallelic mutation in the RPE65 gene and who still have sufficient viable retinal cells in the OCT¹⁰. Applied via subretinal injection, this medication uses a modified virus to introduce a normal copy of the gene into the retinal cells, causing the defective cells to produce the protein that converts light into a sensory signal conducted by the optic nerve^{10,11}.




Figure 2. Retinography of the left eye showing pigmented lumps looking like bone spicules in the periphery of the retina, suggesting unilateral retinitis pigmentosa.




Figure 3. Fluorescein angiography of the left eye, showing diffuse hypofluorescent areas of blockade (hyperplasia of the retinal pigment epithelium) and areas of window-effect hyperfluorescence (rarefaction of the retinal pigment epithelium).




Figure 4. Visual field test of the left eye, showing generalized constriction of isopters (tubular field) with preservation of a central field.

For secondary PRP, the cause must be treated, which for syphilis would mean the use of benzathine or crystalline penicillin at the recommended doses and routes of administration. However, for the patient in question, no specific treatment was instituted, following the guidance of an infectiologist because the patient had already been previously treated with intramuscular penicillin. So, a biannual follow-up was selected.


There are numerous possible causes of cell injury that can lead to mobilization of the pigment epithelium, photoreceptor injury, and pigment deposition

similar to the case described. The existence of isolated URPa clinical entity is controversial, primarily because of the difficulty of ruling out secondary causes, including syphilis, whose incidence in both young and elderly people has been increasing greatly in Brazil. However, a thoroughly collected clinical history can guide the reasoning and diagnosis.


REFERENCES

1. Tayah D, Angelucci RI, Sampaio P, Rehder JRCL. Retinose Pigmentar. *Arq Med ABC*. 2004;29:82-6.
2. Bowling B. Kanski *Oftalmologia Clínica: Uma Abordagem Sistemática*. GEN Guanabara Koogan ed. 2016.
3. Rios DFC, Carneiro LFS, Cunha AAF, Dalle CBM, Frasson M. Retinose pigmentar unilateral ou pseudoretinose pigmentar?: relato de caso. *Arq Bras Oftalmol*. 2013;76(6):383-5.
4. Vela JI, Marcantonio I, Díaz-Cascajosa J, Crespí J, Buil JA. Progression of retinal pigmentation mimicking unilateral retinitis pigmentosa after bilateral pars planitis: a case report. *BMC Ophthalmol*. 2018;18(1):242.
5. François J, Verriest G. Rétinopathie pigmentaire unilatérale. *Ophthalmologica*. 1952;124(2):65-88
6. Aragão REM, Barreira IMA, Bastos ASV, Carneiro GJAM, Oria TPC. Unilateral retinitis pigmentosa: case report. *Rev Med UFC*. 2015;55(2):54-8.
7. Duncan JL, Pierce EA, Laster AM, Daiger SP, Birch DG, Ash JD, Iannaccone A, Flannery JG, Sahel JA, Zack DJ, Zarbin MA, and the Foundation Fighting Blindness Scientific Advisory Board. Inherited Retinal Degenerations: Current Landscape and Knowledge Gaps. *Transl Vis Sci Technol*. 2018;7(4):6.
8. Cestari AT, Sallum JMF, Conti ML, Tagliari TI, Barboza MNC. Retinose pigmentada unilateral secundária a trauma: relato de caso. *Arq Bras Oftalmol*. 2012;75(3):210-2 .
9. Weller JM, Michelson G, Juenemann AG. Unilateral retinitis pigmentosa: 30 years follow-up. *BMJ Case Rep*. 2014 Feb 10;2014:bcr2013202236.
10. Luxturna [prescribing information]. Philadelphia, PA; Spark Therapeutics, Inc. December 2017.
11. Luxturna™ (Voretigene Neparvovec-Rzyl) UnitedHealthcare Commercial Medical Benefit Drug Policy Effective 11/01/2019 Proprietary Information of UnitedHealthcare. Copyright 2019

AUTHOR'S INFORMATION



» **Samilla Augusto Vieira de Araujo:**
<https://orcid.org/0000-0002-7974-4680/>
<http://lattes.cnpq.br/2910111629422356>



» **Renata Zaltron Neumann**
<https://orcid.org/0000-0001-8611-5797>
<http://lattes.cnpq.br/2323154650022034>



» **Francyne Veiga Reis Cyrino**
<https://orcid.org/0000-0002-1892-6210>
<http://lattes.cnpq.br/0720130883701897>